Mexican flu profit maker for pharmacists
Pharmaceutical multinationals benefit from demand for anti-flu funding
July 23, 2009
Rotterdam, July 23. The pharmaceutical industry is relatively immune to the economic downturn. The big pharmaceutical companies in the world expected to significantly benefit from the sale of medicines against the Mexican flu. That was yesterday and today when some major manufacturers of anti-flu funding their half-year figures published.
According to a report by the U.S. investment bank JP Morgan have governments worldwide 600 million influenza vaccine doses ordered and is on top of a market for 342 million doses. This provides the pharmaceutical industry had a turnover of up to 4.8 billion euros. Especially the Swiss Roche and the British GlaxoSmithKline (GSK) will benefit. Sanofi-Aventis, Novartis and Baxter also pick up a grain them.
Tamiflu and Relenza
Roche announced that the production of the Tamiflu anti-flu means would increase to 400 million doses in 2010. The sale of the drug increased in recent times with more than 200 percent. According to Roche can continue to meet the demand.
Competitor Glaxo Smith Kline (GSK), the production of virus inhibitor Relenza triple of 60 million to 190 million doses annually. The company is also a vaccine against the Mexican flu and already received orders for 195 million vaccines.
Sanofi-Pasteur, the vaccintak of Sanofi-Aventis, reported a production capacity of 270 million vaccines annually.
Worldwide deceased for more than 700 people at the Mexican flu, caused by the H1N1 influenza virus. According to the World Health Organization, the pandemic in the coming months to expand rapidly.
Even without the flu, the Mexican pharmaceutical industry well. The figures show that it represents little sensitive to the recession. The results of the industry are mainly affected by the cost of acquisitions that they frequently do, but that his one-time effects. Most companies are very optimistic about the future.
U.S. Pfizer, the largest pharmaceutical manufacturer in the world, reported yesterday a quarter of nearly 11 billion dollars (7.7 billion euros) and a quarterly profit of 2.26 billion dollars. That was slightly lower than the results in the same period the previous year (2.78 billion dollars), but the company was that due to the strong dollar. The company is branch Wyeth to take an amount of 68 billion euros. Pfizer nevertheless increased the expectations for the year.
Number 2 in the world in terms of drugs, GSK, in the second quarter recorded a turnover of 6.75 billion pounds (7.8 billion euro) and earnings per share of 31 pence (36 cents). The British company says to have competition from generic drugs in the U.S., but is also optimistic about the future. It has many new medicines recorded revenue will generate.
The Swiss Roche today announced a half year profit of 4.1 billion Swiss francs (2.7 billion euros) are known. That was 1.6 billion francs less than in 2008, mainly because the acquisition of the remaining stake in biotech company Genentech profit bustle.